These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 35868965

  • 21. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T.
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
    [Abstract] [Full Text] [Related]

  • 22. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C, García Fadul C, Laporta R, Portero F, Millan I, Ussetti P.
    Ann Transplant; 2015 Nov 05; 20():661-6. PubMed ID: 26537426
    [Abstract] [Full Text] [Related]

  • 23. High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis.
    Gupta S, Mitchell JD, Markham DW, Mammen PP, Patel PC, Kaiser P, Ring WS, DiMaio JM, Drazner MH.
    J Heart Lung Transplant; 2008 May 05; 27(5):536-9. PubMed ID: 18442720
    [Abstract] [Full Text] [Related]

  • 24. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V.
    Transpl Infect Dis; 2018 Aug 05; 20(4):e12896. PubMed ID: 29602266
    [Abstract] [Full Text] [Related]

  • 25. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J, Heredia-Pimentel A, Rojas-Campos E, Ramírez Flores D, Cerrillos-Gutierrez JI, Miranda-Díaz AG, Evangelista-Carrillo LA, Martínez-Martínez P, Jalomo-Martínez B, Gonzalez-Espinoza E, Gómez-Navarro B, Medina-Pérez M, Nieves-Hernández JJ.
    Int J Infect Dis; 2021 Jun 05; 107():18-24. PubMed ID: 33862205
    [Abstract] [Full Text] [Related]

  • 26. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.
    J Clin Virol; 2015 Oct 05; 71():73-5. PubMed ID: 26318605
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of the fully automated LIAISON®XL chemiluminescence analyzer for QuantiFERON®-CMV testing in transplant recipients.
    Mafi S, Alain S, Hantz S.
    J Clin Virol; 2023 Sep 05; 166():105550. PubMed ID: 37527584
    [Abstract] [Full Text] [Related]

  • 28. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, Hollinger EF, Olaitan OK, Jensik S, Geyston J, Brokhof MM, Hodowanec AC, Hertl M, Simon DM.
    Transplant Proc; 2016 Sep 05; 48(6):2056-2064.e1. PubMed ID: 27569944
    [Abstract] [Full Text] [Related]

  • 29. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V, Sintes H, López-Gallo C, Delgado M, Santos F, Zurbano F, Solé A, Gavaldá J, Borro JM, Redel-Montero J, Cifrian JM, Pastor A, Román A, Ussetti P.
    Transpl Infect Dis; 2017 Jun 05; 19(3):. PubMed ID: 28294487
    [Abstract] [Full Text] [Related]

  • 30. QuantiFERON-CMV and monitor predict cytomegalovirus, mortality, and graft-versus-host disease in transplant recipients.
    Souan L, Jazar HA, Nashwan S, Sughayer MA.
    J Med Virol; 2023 Nov 05; 95(11):e29250. PubMed ID: 38009250
    [Abstract] [Full Text] [Related]

  • 31. Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study.
    Ju C, Wang X, Xu X, Xie S, Cao Q, Lin W, Zhang J, Xu Y, Lian Q, Huang D, Chen R, He J.
    BMC Infect Dis; 2022 Nov 22; 22(1):872. PubMed ID: 36418967
    [Abstract] [Full Text] [Related]

  • 32. Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial.
    Manuel O, Laager M, Hirzel C, Neofytos D, Walti LN, Hoenger G, Binet I, Schnyder A, Stampf S, Koller M, Mombelli M, Kim MJ, Hoffmann M, Koenig K, Hess C, Burgener AV, Cippà PE, Hübel K, Mueller TF, Sidler D, Dahdal S, Suter-Riniker F, Villard J, Zbinden A, Pantaleo G, Semmo N, Hadaya K, Enríquez N, Meylan PR, Froissart M, Golshayan D, Fehr T, Huynh-Do U, Pascual M, van Delden C, Hirsch HH, Jüni P, Mueller NJ, Swiss Transplant Cohort Study (STCS).
    Clin Infect Dis; 2024 Feb 17; 78(2):312-323. PubMed ID: 37738676
    [Abstract] [Full Text] [Related]

  • 33. High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis.
    Kabbani D, Hirji A, Hernandez C, Malhi H, Mabilangan C, Chandrarathne S, Halloran K, Weinkauf J, Kapasi A, Lien D, Preiksaitis J, Cervera C.
    Transpl Infect Dis; 2019 Aug 17; 21(4):e13094. PubMed ID: 30985048
    [Abstract] [Full Text] [Related]

  • 34. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug 17; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 35. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?
    Schoeppler KE, Lyu DM, Grazia TJ, Crossno JT, Vandervest KM, Zamora MR.
    Am J Transplant; 2013 Feb 17; 13(2):376-82. PubMed ID: 23205887
    [Abstract] [Full Text] [Related]

  • 36. Torque teno virus viremia and QuantiFERON®-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients.
    Mafi S, Essig M, Rerolle JP, Lagathu G, Crochette R, Brodard V, Schvartz B, Gouarin S, Bouvier N, Engelmann I, Garstka A, Bressollette-Bodin C, Cantarovitch D, Germi R, Janbon B, Archimbaut C, Heng AE, Garnier F, Gomes-Mayeras M, Labrunie A, Hantz S, Alain S.
    Front Med (Lausanne); 2023 Feb 17; 10():1180769. PubMed ID: 37425298
    [Abstract] [Full Text] [Related]

  • 37. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F, Khadzhynov D, Schrezenmeier E, Lehner L, Budde K, Staeck O.
    Transplant Proc; 2017 Dec 17; 49(10):2280-2284. PubMed ID: 29198661
    [Abstract] [Full Text] [Related]

  • 38. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT, Tsapepas DS, Li H, Anamisis A, Martin ST.
    Prog Transplant; 2015 Mar 17; 25(1):39-44. PubMed ID: 25758799
    [Abstract] [Full Text] [Related]

  • 39. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 17; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 40. Early versus delayed initiation of cytomegalovirus prophylaxis after liver transplant.
    Magid M, Byrns J, Gommer J, Yang Z, Lee HJ, Harris M.
    Pharmacotherapy; 2022 Aug 17; 42(8):634-640. PubMed ID: 35748517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.